by The Europe IV hydration therapy market comprises intravenous fluids used for various purposes such as correcting fluid and electrolyte balance, dissolving and diluting substances for injection, and providing hydration. IV hydration involves delivering prescribed fluids, vitamins, and other nutrients and medications straight into the bloodstream. It is commonly used for hangovers, headaches, jet lag, nausea, or any condition requiring rapid rehydration. The Europe IV hydration therapy market is estimated to be valued at US$ 301.46 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Europe IV hydration therapy are Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals, Abcam plc. The key players are focused on new product development and engaged in strategic collaboration activities to expand their geographic footprint.
The growing patient preference for IV hydration therapy for quick rehydration is one of the major factors driving the market growth. IV therapy provides immediate hydration and allows absorption of fluids and nutrients quicker than oral rehydration. Furthermore, rising consumer awareness about health and wellness is also propelling the demand.
The Europe IV hydration therapy market Size is witnessing strong growth in the key markets of U.K, Germany, France and Italy. These countries have modern and advanced healthcare infrastructure and rising medical tourism which is attracting patients for IV hydration treatments. Additionally, key players are focused on expanding their presence across European countries will further aid revenue generation in the European region over the forecast period.
Market key trends
Home IV therapy is gaining traction in the Europe region. With the advancements in medical technology, it is now possible to have IV therapy administered at home. Home IV services offer convenience to patients and help avoid hospital visits and costs. This emerging trend is expected to positively influence the European IV hydration therapy market during the forecast period.
Porter’s Analysis
Threat of new entrants: High capital requirements and stringent regulations make Europe IV Hydration Therapy market less attractive for new competitors. Bargaining power of buyers: Large number of buyers leads to lower bargaining power of individual buyers. Bargaining power of suppliers: Few major suppliers service the European IV Hydration Therapy market giving them some bargaining power. Threat of new substitutes: There are limited substitutes for IV hydration therapy hence threat is low. Competitive rivalry: Large market presence of key players like Thermo Fisher Scientific, Bio-rad Laboratories and Lonza Group leads to high rivalry.
Geographical regions with highest market value
United Kingdom accounts for the largest share in the European IV Hydration Therapy market in terms of value. This can be attributed to rising health awareness, growing lifestyle diseases and increasing aged population in the country. Germany holds the second largest market share due to presence of developed healthcare infrastructure and favorable reimbursement policies. France, Italy, Spain follow United Kingdom and Germany in terms of IV Hydration Therapy market value in Europe.
Fastest growing geographical region
Central and Eastern Europe region especially countries like Poland, Czech Republic, Hungary is projected to witness highest CAGR in the European IV Hydration Therapy market during the forecast period. This rapid growth can be accredited to improving economic conditions, rising healthcare investments and increasing focus towards prevention and wellness in these countries.
